Core Viewpoint - Vaxcyte, Inc. is a clinical-stage vaccine innovation company focused on developing high-fidelity vaccines to combat bacterial diseases, with upcoming participation in the Guggenheim SMID Cap Biotech Conference [1] Company Overview - Vaxcyte is engineering broad-spectrum conjugate and novel protein vaccines aimed at preventing or treating bacterial infectious diseases [3] - The company is developing VAX-31, a 31-valent PCV for preventing invasive pneumococcal disease (IPD) in adults and infants, and VAX-24, a 24-valent PCV currently in Phase 2 infant study [3] - Both VAX-31 and VAX-24 aim to improve upon existing PCVs by covering serotypes responsible for high case-fatality rates and antibiotic resistance [3] Technology and Innovation - Vaxcyte utilizes modern synthetic techniques, including advanced chemistry and the XpressCF™ cell-free protein synthesis platform, to produce complex vaccines more efficiently [4] - The company's approach is designed to enhance the immunological benefits of vaccines while accelerating the development process [4] Pipeline Candidates - Vaxcyte's pipeline includes VAX-A1 for preventing Group A Strep infections, VAX-PG for slowing periodontal disease progression, and VAX-GI for preventing Shigella [4]

Group 1 - The article emphasizes the importance of financial modeling techniques, particularly DCF analysis, to identify underlying assumptions in stock valuations [1] - A disciplined risk management strategy is advocated, utilizing a barbell approach that allocates 90% to safe assets and 10% to high-growth opportunities [1] - The DCF model assumes free cash flow starts at a baseline and grows at a constant annual rate over eight years, with a terminal value calculated using the Gordon Growth Model [1] Group 2 - Key assumptions in the DCF model include a constant growth rate and discount rate, with the discount rate exceeding the perpetual growth rate to ensure a finite terminal value [1] - The article highlights the need for accurate free cash flow projections to capture future performance without unexpected changes [1]

Core Insights - Vaxcyte has initiated a Phase 2 study for VAX-31, a 31-valent pneumococcal conjugate vaccine (PCV) aimed at preventing invasive pneumococcal disease (IPD) in infants, with topline data expected in mid-2026 and booster dose data approximately nine months later [1][2][3] - VAX-31 is designed to cover approximately 94% of IPD and 93% of acute otitis media in U.S. children under five, offering broader protection compared to current standard-of-care PCVs [2][7] - The study will compare VAX-31's safety, tolerability, and immunogenicity against Prevnar 20 (PCV20) in a randomized, double-blind format across two stages involving around 798 infants [3][4][5] Company Overview - Vaxcyte is focused on developing high-fidelity vaccines to combat bacterial diseases, with VAX-31 being the broadest-spectrum PCV candidate currently in clinical trials [9][10] - The company also has VAX-24, a 24-valent PCV candidate, which is in a Phase 2 study and aims to cover more serotypes than any existing infant PCV [9] - Vaxcyte employs modern synthetic techniques for vaccine development, including the XpressCF™ cell-free protein synthesis platform, to enhance the efficiency and immunological benefits of its vaccines [10] Industry Context - Pneumococcal disease, caused by Streptococcus pneumoniae, is a significant public health threat, particularly in children under five, leading to high rates of vaccine-preventable deaths globally [6] - The World Health Organization has identified Streptococcus pneumoniae as a top antibiotic-resistant pathogen, highlighting the urgent need for vaccines with broader coverage [6] - Current vaccines are insufficient to address the persistent threat of IPD, which includes severe conditions like meningitis and bacteremia, underscoring the importance of Vaxcyte's innovative vaccine candidates [2][6]

   -- VAX-31 Infant Indication: Investigational New Drug Application Cleared by FDA; Company Expects to Initiate VAX-31 Infant Phase 2 Study by the End of January 2025 -- -- VAX-31 Adult Indication: Breakthrough Therapy Designation Granted by FDA; Company Plans to Initiate Adult Phase 3 Pivotal, Non-Inferiority Study by Mid-2025 -- -- VAX-31, Designed to Cover Currently Circulating and Historically Prevalent Strains, is Being Studied for the Prevention of Invasive Pneumococcal Disease in the Pediatric and A ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ___________________________________________________ FORM 10-Q ___________________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | |------------------------------------------------ ...

Exhibit 99.1 Vaxcyte Reports Third Quarter 2024 Financial Results and Provides Business Update -- Company Reported Positive Topline Safety, Tolerability and Immunogenicity Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate, in Adults Aged 50 and Older -- -- PCV Adult Indication: VAX-31 Selected to Advance to Phase 3 Program; Initiation of Phase 3 Pivotal, Non-Inferiority Study Expected by Mid-2025 and Announcement of Topline Safety, Tolerability and Immunogenic ...

-- Company Reported Positive Topline Safety, Tolerability and Immunogenicity Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate, in Adults Aged 50 and Older -- -- PCV Adult Indication: VAX-31 Selected to Advance to Phase 3 Program; Initiation of Phase 3 Pivotal, Non-Inferiority Study Expected by Mid-2025 and Announcement of Topline Safety, Tolerability and Immunogenicity Data in 2026 -- -- PCV Pediatric Indication: VAX-24 Infant Phase 2 Study Topline Data from ...

SAN CARLOS, Calif., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinicalstage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that Company management will participate in a fireside chat at the 2024 Cantor Global Healthcare Conference on Wednesday, September 18, at 10:20 a.m. ET / 7:20 a.m. PT. A live webcast of the fireside chat can be accessed through the Investors & Media section of the C ...

MicroStockHub Vaxcyte, Inc. (NASDAQ:PCVX) is developing next-generation vaccines to prevent and treat bacterial infections through its novel Cell-Free Protein Synthesis [XpressCF] platform. PCVX's technology overcomes the limitations of conventional, cell-based vaccine approaches, delivering broad-spectrum vaccines. Its main value drivers are VAX-31 and VAX-24, which are pneumococcal conjugate vaccines that protect against invasive pneumococcal disease [IPD]. VAX-31 is in Phase 1/2 trials and is quickly pro ...

SAN CARLOS, Calif., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinicalstage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today the closing of its previously announced underwritten public offering of 12,087,378 shares of common stock at a public offering price of $103.00 per share and prefunded warrants to purchase 2,427,184 shares of common stock at a public offering price of $102.999 per pr ...